Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹17,150 Cr
Revenue (TTM)
₹4,560 Cr
Net Profit (TTM)
₹1,557 Cr
ROE
28 %
ROCE
32.8 %
P/E Ratio
11
P/B Ratio
2
Industry P/E
46.99
EV/EBITDA
6.9
Div. Yield
0.6 %
Debt to Equity
0
Book Value
₹490.8
EPS
₹86.9
Face value
2
Shares outstanding
179,109,870
CFO
₹6,110.50 Cr
EBITDA
₹8,979.00 Cr
Net Profit
₹7,033.60 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| 6.1 | 8.3 | 3.9 | 19.7 | 21.3 | 3.1 | 7.5 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| -35.4 | 69.5 | 44.5 | -37.9 | -6.5 | 55.6 | -14.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Natco Pharma
|
957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 676.3 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 | |
| 306.3 | 11,719.9 | 2,051.5 | 180.5 | 11.6 | 7.7 | 58.1 | 3.1 | |
| 587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
From past growth to future prosperity
6 min read•By Rajan Gulati
Three mid caps that are up for easy grabs
5 min read•By Yash Rohra
4 min read•By Rajan Gulati
1 min read•By Research Desk
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It... offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. Read more
Incorporated
1981
Chairman
V C Nannapaneni
Managing Director
V C Nannapaneni
Group
Natco
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Natco Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsClarification On Volume Movement Of Shares
25-Feb-2026Clarification sought from Natco Pharma Ltd
25-Feb-2026Rumour verification - Regulation 30(11)
25-Feb-2026Clarification sought from Natco Pharma Ltd
24-Feb-2026
The share price of Natco Pharma Ltd is ₹957.90 (NSE) and ₹957.50 (BSE) as of 18-Mar-2026 IST. Natco Pharma Ltd has given a return of 21.28% in the last 3 years.
The P/E ratio of Natco Pharma Ltd is 11.01 times as on 18-Mar-2026, a 77 discount to its peers’ median range of 46.99 times.
The P/B ratio of Natco Pharma Ltd is 1.95 times as on 18-Mar-2026, a 35 discount to its peers’ median range of 3.02 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
7.57
|
1.88
|
|
2024
|
12.27
|
2.91
|
|
2023
|
14.38
|
2.11
|
|
2022
|
81.30
|
3.24
|
|
2021
|
34.16
|
3.67
|
The 52-week high and low of Natco Pharma Ltd are Rs 1,059.00 and Rs 726.80 as of 19-Mar-2026.
Natco Pharma Ltd has a market capitalisation of ₹ 17,150 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Natco Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹15.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.